Applicant Name:

UNIVERSITY of MARYLAND
MARLENE AND STEWART GREENEBAUM
COMPREHENSIVE CANCER CENTER

Attachment A

NCI requires an explanation of the cancer relevancy of your work. Provide specific examples of how your work is relevant to the prevention, diagnosis, treatment or investigation of cancer.

Planned Cancer Research Interactions/Collaborations:

Attachment B

UNIVERSITY OF MARYLAND PROGRAM IN ONCOLOGY
REQUEST FOR APPOINTMENT IN THE UNIVERSITY OF MARYLAND PROGRAM IN ONCOLOGY

I hereby request full/new/affiliate membership in the University of Maryland Program in Oncology. I understand and accept the following obligations that such an appointment confers:

1. All members are expected to interact within and among each UMGCCC Research Program through routine collaborations, monthly program seminars, special seminars, grant/contract application development groups and at other UMGCCC events.

2. Members must respond to requests to assign Shared Resource utilization to their cancer relevant publications.

3. All members are expected to properly cite the UMGCCC NCI CCSG in their publications and presentations: P30 CA134274

4. All members are expected to participate in Pilot Project Award application study sections.

5. Participation is expected in at least 50% of regularly scheduled UMGCCC scientific meetings, town halls and other scientific events to promote collaboration.

6. Prompt response and completion of all surveys.

7. Volunteer to host trainees.

8. Contribute to UMGCCC committees, grants, contracts, national and regional service, and media features involving members.

9. Completion of baseline IDEA survey.

10. Participate in UMGCCC SPORE, U54, and other grant applications.

Applicant Name (please print): _____

Applicant Signature: _____

Attachment C

Applicant Name:	
UMMS Institution:	
University of Maryland Campus:	
Academic Department:	
Location of principle clinical practice:	
Work Address:	
Email:	
Phone:	
Gender:	◯ Male ◯ Female
Gender Identity: Which of these terms best express how you describe your gender identity?	◉ **Cisgender:** current gender identity corresponds with sex assigned at birth ☐ Cisgender Man ☐ Cisgender Woman ◯ **Transgender:** current gender identity does not correspond with sex assigned at birth ☐ Transgender Man ☐ Transgender Woman ◯ **Non-Binary:** any gender identity that does not fit into the gender binary of male and female ◯ Others (Please specify) ◯ Prefer not to say
Race/Ethnicity: Select all that apply	☐ White ☐ Hispanic ☐ Black or African American ☐ Asian ☐ American Indian or Alaska Native ☐ Middle Eastern or North African ☐ Native Hawaiian or Other Pacific Islander ☐ Other (specify): ☐ Prefer not to say

Disadvantage status Does any of the following situations apply to you? (Check all that apply)	☐ a. I was or am currently homeless in the US.
	☐ b. I was or currently am in the foster care system in the US.
	☐ c. I was eligible for the US Federal Free and Reduced Lunch Program for two or more years.
	☐ d. I have/had no parents or legal guardians who completed a bachelor's degree.
	☐ e. I was or currently am eligible for US Federal Pell grants.
	☐ f. As a parent or child, I receive/d support from the US Special Supplemental Nutrition Program for Women, Infants and Children (WIC)
	☐ g. I grew up in a U.S. rural area (https://data.hrsa.gov/tools/rural-health) OR a CMMS-designated Low-Income and Health Professional Shortage Area (https://tinyurl.com/38u894vu)
	☐ h. Prefer not to say
Disability status Do you have any disability?	◯ No
	◯ Prefer not to say
	◯ Yes (check all that apply) ☐ i. Visual disability ☐ ii. Hearing disability ☐ iii. Walking disability ☐ iv. Lifting disability ☐ v. Cognitive disability

Program in Oncology Research Programs

Please indicate your primary (1) and secondary (2) interest by program.

☐ **Experimental Therapeutics Program**
Contact: Maria Baer, M.D., Professor, Department of Medicine
Feyruz Rassool, Ph.D., Professor, Department of Radiation Oncology

Program Description:
The overarching goal of the Experimental Therapeutics (ET) Program of UMGCCC is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to study their findings in the clinical setting. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Molecular targets—develop and test new cancer therapies based on novel molecular targets; Theme 2: Treatment delivery—develop and test novel formulations and delivery strategies for cancer treatments and new regional therapies; and Theme 3: Radiation—develop and test novel strategies for utilizing ionizing and nonionizing radiation and for radiation sensitization and protection in the multimodality management of cancers.

☐ **Tumor Immunology and Immunotherapy Program**
Contact: Xuefang Cao, Ph.D., Associate Professor, Microbiology & Immunology
Aaron Rapoport, M.D., Professor, Department of Medicine

Program Description:
The principal scientific goals of the Program are to develop, characterize, and implement immunological approaches for the prevention, treatment and monitoring of cancer and cancer progression. To achieve this goal, the program focuses on enhancing adaptive and innate antitumor responses and mitigating immunoinhibitory signals. The TII Program's research and clinical endeavors focus on the following themes: (1) Cell-based cancer immunotherapies— Develop novel approaches to elicit active tumor immunity capable of reducing or preventing malignant cell growth, (2) Inhibiting immunosuppression—Develop strategies to overcome tumor immune evasion including the blocking of negative signals received by T cells and impeding the activity of suppressive cell types, and (3) Cancer and inflammation—Elucidate the roles and associations between infection, inflammatory responses and cancer development including the generation of an immunosuppressive tumor microenvironment.

☐ **Hormone Related Cancers Program**
Contact: Stuart S. Martin, Ph.D., Professor, Department of Physiology
Arif Hussain, M.D., Professor, Department of Medicine

Program Description:
The overarching goal of the Hormone Responsive Cancers (HRC) Program of UMGCCC is to reduce morbidity and mortality from cancers of hormone-responsive tissues. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Therapeutic strategies against hormone-responsive tumors—identify new agents to target malignancies that remain responsive to hormone manipulation; Theme 2: Mechanisms of innate and acquired hormone resistance—identify and target the mechanisms that confer de novo or acquired resistance to hormone manipulation; and Theme 3: Invasion and metastasis—identify the mechanisms that promote tumor dissemination and identify therapeutic strategies to target these mechanisms.

☐ **Molecular and Structural Biology Program**

Contact: David J. Weber, Ph.D., Professor, Department of Biochemistry & Molecular Biology
France Carrier, Ph.D., Professor, Department of Radiation Oncology

Program Description:
The overall goal of the MSB Program is to elucidate molecular mechanisms and cellular processes that are altered in cancer and translate these findings towards treating cancer. The research interests of the Program members can be divided into three broad themes including: (1) DNA damage, repair, and genomic instability and to characterize how defects in DNA repair lead to genomic instability and carcinogenesis; (2) Dysregulation of transcriptional & posttranscriptional control and to determine how defects in gene expression processes lead to dysregulation of protein expression in cancer; (3) Cancer cell signaling and to delineate how signaling pathways are dysregulated in cancer. There is also an effort to identify specific biomolecules that can be targeted for suppressing cancer. In this regard, the basic science coming from MSB members laboratories are evaluated for their potential as therapeutic targets and structure-based drug design approaches are used to develop small molecules and/or biologics that will serve as leads for the development of novel therapeutic agents.

☐ **Population Science Program**

Contact: Cheryl L. Knott, Ph.D., Professor, Department of Behavioral and Community Health
Sally N. Adebamowo, MBBS, Msc, ScD, Associate Professor, Department of Epidemiology & Public Health

Program Description:
The overall goals of the Population Science (PS) Program are to identify determinants of cancer etiology, cancer-related behaviors, and survivorship and to translate basic discoveries into behavioral cancer prevention and control interventions. To achieve these goals, research addresses four themes: 1) epidemiology of infection- and hormone-related cancers; 2) tobacco and nicotine; 3) equity in cancer prevention and early detection; and 4) cancer survivorship. The program has unique strengths and a significant emphasis on reducing cancer disparities, working directly with populations in the UMGCCC catchment area.